Title: Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces
boulardii supplements on eradication of Helicobacter pylori
Version: 1 Date: 01 Jul 2024
Reviewer:  Zohreh Bari
Reviewer's report:
Thank the authors for their study. They have introduced the protocols, interpreted and discussed
the results precisely.
However, I have some minor comments to be addressed.
1- In results, it is mentioned that 11 patients reported adverse events in the ECAB group,
including six cases melena. Since Bismuth can cause dark stool, was the bismuth-related dark
stool differentiated from real melena?
2- It would be better to include and compare the endoscopic findings of the patients of both
groups as their baseline characteristics in table 1, since patients with non-ulcer dyspepsia are
more resistant to H. pylori eradication than those with peptic ulcer disease.
Title: Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces
boulardii supplements on eradication of Helicobacter pylori
Version: 1 Date: 01 Jul 2024
Reviewer:  Zohreh Bari
Reviewer's report:
Thank the authors for their study. They have introduced the protocols, interpreted and discussed
the results precisely.
However, I have some minor comments to be addressed.
1- In results, it is mentioned that 11 patients reported adverse events in the ECAB group,
including six cases melena. Since Bismuth can cause dark stool, was the bismuth-related dark
stool differentiated from real melena?
2- It would be better to include and compare the endoscopic findings of the patients of both
groups as their baseline characteristics in table 1, since patients with non-ulcer dyspepsia are
more resistant to H. pylori eradication than those with peptic ulcer disease.
Please review this paper.
user
Title: Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces
boulardii supplements on eradication of Helicobacter pylori
Version: 1 Date: 01 Jul 2024
Reviewer:  Zohreh Bari
Reviewer's report:
Thank the authors for their study. They have introduced the protocols, interpreted and discussed
the results precisely.
However, I have some minor comments to be addressed.
1- In results, it is mentioned that 11 patients reported adverse events in the ECAB group,
including six cases melena. Since Bismuth can cause dark stool, was the bismuth-related dark
stool differentiated from real melena?
2- It would be better to include and compare the endoscopic findings of the patients of both
groups as their baseline characteristics in table 1, since patients with non-ulcer dyspepsia are
more resistant to H. pylori eradication than those with peptic ulcer disease.
assistant